Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.
Semaglutide, the main ingredient in Ozempic and Wegovy, is in ongoing shortage, the FDA says, and compounded versions of these drugs are still permitted. The U.S. Food and Drug Administration (FDA ...
A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic ...
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback